October 2024
|
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
Silke Gillessen, Aurelius Omlin et al. European Urology ✅Take Home The 2024 Advanced Prostate Cancer Consensus Conference surveyed 120 experts on 183 key questions to address gaps in high-level evidence regarding clinical management, yielding varying degrees of consensus that can guide clinicians and inform future research priorities while emphasizing the need for individualized treatment decisions. https://www.sciencedirect.com/science/article/pii/S0302283824026101 79 |
|
Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography
Rajwa P…Gandaglia G European Urology oncology ✅Take home This study of 116 patients with de novo oligometastatic prostate cancer detected via PSMA-PET imaging found that cytoreductive radical prostatectomy (cRP) was well tolerated, achieving a 1-year urinary continence rate of 82% and 2-year rates of castration-resistant prostate cancer-free survival and overall survival at 85.8% and 98.9%, respectively, while emphasizing the potential for early progression and the necessity for multimodal therapy. https://euoncology.europeanurology.com/article/S2588-9311(23)00197-9/fulltext 18 |
|
Benefit of Whole-Pelvis Radiation for Patients With Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis
Marcq Gautier…Kassouf K JCO (ASCO) ✅Take Home Whole-pelvis radiation therapy (WP-RT) is associated with improved cancer-specific survival and overall survival compared to bladder-only radiation therapy (BO-RT) in patients with muscle-invasive bladder cancer, though further randomized trials are needed to confirm these findings. https://ascopubs.org/doi/10.1200/JCO.23.02718 26 |
|
Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: G-MINOR Trial
Morgan T...Cher M European Urology ✅Take Home The Decipher genomic classifier increased the likelihood of adjuvant treatment in high-risk prostate cancer patients post-surgery, but it did not significantly affect overall treatment rates or patient-reported outcomes, and its long-term cancer control benefits are still uncertain. https://www.europeanurology.com/article/S0302-2838(24)02604-6/abstract 18 |
|
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer
Lerner S…Schuckman A NEJM ✅Take Home The study found that extended lymphadenectomy does not improve disease-free or overall survival compared to standard lymphadenectomy in patients with muscle-invasive bladder cancer undergoing radical cystectomy and is associated with higher perioperative morbidity and mortality. https://www.nejm.org/doi/full/10.1056/NEJMoa2401497 29 |
|
PACE B: Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer
Van As N…Hall E NEJM ✅Take Home This study found that stereotactic body radiotherapy (SBRT) is noninferior to conventional radiotherapy for low-to-intermediate-risk localized prostate cancer, though it carries a higher risk of late genitourinary toxicity. https://www.nejm.org/doi/full/10.1056/NEJMoa2403365 54 |
|
Therapy Optimization in the Management of Metastatic Hormone-sensitive Prostate Cancer: Insights from the ARASENS Study
Merseburger A…Bahl A European Urology (Editorial) ✅Take home The ARASENS study demonstrated that darolutamide combined with androgen deprivation therapy and docetaxel significantly improves prostate-specific antigen responses and delays disease progression in patients with metastatic hormone-sensitive prostate cancer, suggesting the potential for mHSPC to be managed as a chronic disease, especially in those with low-volume cancer. https://www.europeanurology.com/article/S0302-2838(24)02364-9/abstract#f0005 44 |
|
Pre-treatment metastatic biopsy:
a step towards precision oncology for urothelial cancer Klumper N…Eckstein M Nature reviews Urology ✅Take Home The molecular heterogeneity between primary and metastatic tumors in metastatic urothelial cancer (mUC) suggests that fresh metastatic biopsies may improve treatment selection and response predictions, addressing a key limitation of current biomarker integration in clinical practice. https://www.nature.com/articles/s41585-024-00951-2.epdf?sharing_token=EdpWslgxA8ia42DovJYKUdRgN0jAjWel9jnR3ZoTv0OkjBmPUaooN-R_5Z7lgDhMGiBGlN_JhAwATjPD-nun7UYyWAxK4TtXNj_gfZs8rNovNdCeCUBpCGEDi33SLcluf-c5asb1BhylMNF4RkB1olGFUepsWg-9F0XD8Q83fGI%3D |